News stories about BioScrip (NASDAQ:BIOS) have been trending somewhat positive on Monday, according to Accern. Accern scores the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BioScrip earned a media sentiment score of 0.03 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.273059949995 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:
- Insider Buying: BioScrip, Inc. (BIOS) CFO Buys 10,000 Shares of Stock (americanbankingnews.com)
- Daniel E. Greenleaf Acquires 15,000 Shares of BioScrip, Inc. (BIOS) Stock (americanbankingnews.com)
- Technical Focus – BioScrip, Inc. (BIOS) stock price comparison to its 20 SMA – Stocks Gallery (stocksgallery.com)
- BioScrip to Host Meetings at the 8th Annual Craig-Hallum Alpha Select Conference – GlobeNewswire (press release) (globenewswire.com)
A number of research analysts recently weighed in on BIOS shares. BidaskClub lowered shares of BioScrip from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 1st. ValuEngine lowered shares of BioScrip from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Jefferies Group LLC reiterated a “buy” rating and issued a $4.00 price objective (up from $3.00) on shares of BioScrip in a research note on Thursday, August 10th. SunTrust Banks, Inc. upgraded shares of BioScrip from a “hold” rating to a “buy” rating and lifted their price objective for the company from $3.25 to $3.75 in a research note on Thursday, August 10th. Finally, Zacks Investment Research lowered shares of BioScrip from a “buy” rating to a “hold” rating in a research note on Monday, August 14th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $3.60.
Shares of BioScrip (NASDAQ:BIOS) traded up $0.03 during trading hours on Monday, reaching $2.11. 781,900 shares of the company’s stock traded hands, compared to its average volume of 1,754,143. The company has a quick ratio of 1.60, a current ratio of 1.91 and a debt-to-equity ratio of -6.11. BioScrip has a 1 year low of $0.98 and a 1 year high of $3.39.
BioScrip (NASDAQ:BIOS) last posted its quarterly earnings data on Thursday, November 2nd. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). The firm had revenue of $198.70 million for the quarter, compared to the consensus estimate of $202.91 million. During the same period in the prior year, the company earned ($0.12) earnings per share. The business’s revenue was down 11.5% compared to the same quarter last year. equities analysts expect that BioScrip will post -0.63 earnings per share for the current fiscal year.
In other BioScrip news, Director Coliseum Capital Management, L sold 886,478 shares of the business’s stock in a transaction dated Thursday, August 17th. The shares were sold at an average price of $3.08, for a total value of $2,730,352.24. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Daniel E. Greenleaf acquired 15,000 shares of the firm’s stock in a transaction on Thursday, November 9th. The stock was purchased at an average price of $2.03 per share, for a total transaction of $30,450.00. Following the transaction, the chief executive officer now directly owns 31,000 shares of the company’s stock, valued at approximately $62,930. The disclosure for this purchase can be found here. In the last quarter, insiders sold 3,760,419 shares of company stock worth $11,144,519. 0.80% of the stock is owned by corporate insiders.
BioScrip Company Profile
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with MarketBeat.com's FREE daily email newsletter.